Test of ovarian cancer multiplex xMAP technology panel

Abstract

An ovarian cancer xMAPtechnology panel including leptin, prolactin, osteopontin, IGFII, MIF and CA125 was tested for multiplex measurement and compare to conventional serum markers in ovarian cancer patients and controls with benign ovarian disease.

Keywords

• ovarian cancer
• multiplex
• tumour markers
• panel